Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Impact · against what's priced in

The news is neutral for Eli Lilly as its market dominance and the superior tolerability of Foundayo are already baked into its valuation. For Viking Therapeutics, the move to Phase 3 is a positive step, but significant risks regarding patient discontinuation rates remain a headwind for long-term competitiveness.

LLY+0.00: Already priced in
The price assumes: Current GLP-1 market dominance and the initial U.S. launch of the oral pill Foundayo

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Connected tickers

Track these names every morning.

AARD DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Connected tickers

Track these names every morning.

AARD DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead